Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase II drugs for Refractory Chronic Lymphocytic Leukemia (CLL) have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lisaftoclax’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lisaftoclax (APG -2575) is under development for the treatment of B-cell cancers such as chronic lymphocytic leukemia (CLL), multiple myeloma and acute myeloid leukemia (AML) relapsed and refractory diffuse large B-cell lymphoma, multiple myeloma, mantle cell lymphoma, chronic myelomonocytic leukemia, myelodysplastic syndrome, waldenstrom macroglobulinemia, relapsed/refractory chronic lymphocytic leukemia, T-cell prolymphocytic leukemia (r/r T-PLL), myelodysplastic syndrome, follicular lymphoma, hairy cell leukemia, solid tumors, acute lymphoblastic leukemia and metastatic ER positive, HER2 negative breast cancer. It is administered through oral route as a tablet. The drug candidate acts by inhibiting Bcl-2 protein.
Ascentage Pharma Group International overview
Ascentage Pharma Group International (Ascentage Pharma) is a biotechnology company that discovers and develops targeted small-molecule therapies for the treatment of cancer, hepatitis B and age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company product pipeline includes HQP8361, APG-2449, APG-2575, APG-1252, APG-115, APG-1387, APG-5918, APG-265, AS1266 and UBX1967/1325. Ascentage Pharma lead candidate HQP8361 is a second-generation c-Met kinase inhibitor for the treatment of c-Met positive cancers, gastric cancer, non-small cell lung cancer and liver cancer. It operates research and development centers and production facilities in Hong Kong, China, and the US. Ascentage Pharma is headquartered in Suzhou, Jiangsu, China.
For a complete picture of Lisaftoclax’s drug-specific PTSR and LoA scores, buy the report here.